Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Varicose Vein Surgery Treatment & Management

  • Author: Wesley K Lew, MD; Chief Editor: Vincent Lopez Rowe, MD  more...
 
Updated: Nov 18, 2015
 

Approach Considerations

Surgical removal or obliteration of varicose veins is often for cosmetic reasons alone. Noncosmetic indications include symptomatic varicosities (eg, pain, fatigability, heaviness, recurrent superficial thrombophlebitis, bleeding), or for the treatment of venous hypertension after skin or subcutaneous tissue changes, such as lipodermatosclerosis, atrophie blanche, ulceration, or hyperpigmentation, have developed.[21]

Conservative treatment with stockings and external compression is an acceptable alternative to surgery, but worsening cutaneous findings or symptoms despite these measure usually warrant intervention. Nonetheless, a patient's desire for surgical management over conservative treatment or for cosmetic purposes alone are both reasonable relative indications for surgery.

Patients with venous outflow obstruction should not have their varicosities ablated, because they are important bypass pathways that allow blood to flow around the obstruction.

Those patients who cannot remain active enough to reduce the risk of postoperative deep vein thrombosis (DVT) should not undergo surgery.

Surgery during pregnancy is contraindicated because many varicose veins of pregnancy spontaneously regress after delivery.

Management of varicose veins has evolved over the centuries and will continue to do so. Less invasive techniques continue to be refined, but long-term efficacy must always be questioned and compared with the criterion standard of surgical saphenectomy.

Next

Surgical Therapy

Surgical treatment of varicose veins has been under development for more than 2000 years, but until the present era, relatively little weight was given to the cosmetic outcome of treatment. Current therapies are becoming less invasive and yielding improved recovery, but long-term outcomes are uncertain. Therapies aim to remove the superficial venous system through either surgery, endovenous ablation, or sclerotherapy ablation.[22]

In 90% of cases where venous hypertension is from superficial and perforator vein reflux, removal or obliteration of the great saphenous vein (GSV) alone can resolve the venous hypertension.[6, 23] In the remaining 10%, however, additional treatment to the incompetent perforator veins may be needed. Additionally, if severe deep venous incompetence exists, treatment of the GSV alone usually does not resolve the venous hypertension. In both these cases, additional interventions with subfascial endoscopic perforating vein surgery (SEPS), perforator vein ablation, and/or venous reconstruction can be attempted, but these details are not further discussed in this article.

For now, the authors will discuss the procedures to remove or obliterate the superficial venous system, proceeding from most invasive to least invasive. Historical perspectives, advantages, and disadvantages to each technique will also be addressed. However, prior to any intervention, duplex ultrasonography (US) should always be used to map all major reflux pathways, and a skin marker should be used to mark all surface vessels to be removed.

Open techniques

The Rindfleisch-Friedel procedure of the early 1900s involved one incision to the level of the deep fascia that wrapped around the leg six times, creating a spiral gutter that brought into view a large number of superficial veins, each one of which was ligated. This wound was left open to heal by granulation. The Linton procedure, introduced in the late 1930s, used a large linear medial leg incision that brought into view all the superficial and perforator veins of the leg. Incompetent superficial veins were removed, and perforating veins were interrupted.[24]

In the late 1800s, Trendelenburg introduced a midthigh ligation of the GSV. The outcomes were variable, and this procedure was later modified by Trendelenburg's student Perthes, who advocated a groin incision and a ligation of the GSV at the saphenofemoral junction (SFJ). Later, even better outcomes were found if saphenectomy (removal of the GSV) with ligation at the SFJ was performed in place of ligation alone. In a randomized trial, two thirds of patients treated with ligation without saphenectomy could be expected to need reintervention within 5 years for recurrent reflux, either from recanalization or from collateral formation around the ligated GSV.[24, 25, 26]

Excision of GSV

Surgical removal of the GSV has evolved from large open incisions to less invasive stripping. Original methods of stripping used different devices and variations of techniques. The Mayo stripper was an extraluminal ring that cut the tributaries as it was passed along the vein. The Babcock device was an intraluminal stripper with an acorn-shaped head that pleated up the vein as it pulled the vessel loose from its attachments. The Keller device was an internal wire used to pull the vein through itself, as is done today with perforation-invagination (PIN) strippers.

Currently, the technique of PIN stripping begins with a 2- to 3-cm incision made at the groin crease. The femoral vein and the SFJ are exposed with dissection, and all tributaries of the SFJ must be identified and flush-ligated to minimize the incidence of reflux recurrence.

After ligation and division of the junction, the stripping instrument (usually a stiff but flexible length of wire or plastic) is passed into the GSV at the groin and threaded through the incompetent vein distally to the level of the upper calf. The stripper is brought out through a small (≤5 mm) incision approximately 1 cm from the tibial tuberosity at the knee. An inverting head is attached to the stripper at the groin and is secured to the proximal end of the vein.

The vessel is then inverted into itself, tearing away from each tributary and perforator as the stripper is pulled downward through the leg and out through the incision in the upper calf (see the image below). If desired, a long epinephrine-soaked gauze or ligature may be secured to the stripper before invagination, allowing hemostatic packing to be pulled into place after stripping is complete.

Perforation-invagination (PIN) stripping schematic Perforation-invagination (PIN) stripping schematic.

An older technique of stripping to the ankle (rather than to just the knee) has fallen into disfavor because of a high incidence of complications, including damage to the saphenous nerve, which is closely associated with the vein below the knee.[4]

Excision of SSV

Removal of the small saphenous vein (SSV) is complicated by the variable local anatomy and the risk of injury to the popliteal vein and peroneal nerve. The saphenopopliteal junction (SPJ) must be located by duplex examination before the dissection is begun, and adequate direct visualization of the SPJ is essential.

After ligation and division of the SPJ, the stripping instrument (often a more rigid stripper that facilitates navigation) is passed downward into the distal calf, where it is brought out through a small (2-4 mm) incision. The stripper is secured to the proximal end of the vein, which is invaginated into itself as it is pulled downward from knee to ankle and withdrawn from below.

Stab phlebectomy

Performed by Galen as early as the second century, stab phlebectomy (also referred to as ambulatory phlebectomy) came back into modern favor during the 1960s and has increased in popularity ever since. This procedure is extremely useful for the treatment of residual vein clusters after saphenectomy and for removal of nontruncal tributaries when the saphenous vein is competent.

A microincision is made over the vessel with a tiny blade or a large needle, a phlebectomy hook is introduced into the microincision, and the vein is delivered through the incision. With traction, as long a segment as possible is pulled out of the body until the vein breaks or cannot be pulled any further. Another microincision is made and the process is begun again and repeated along the entire length of the vein to be extracted. Short segments of veins can be removed through tiny incisions without ligatures, and skin closure is not necessary.[4]

Endovascular techniques

Endovenous laser treatment

A laser fiber produces endoluminal heat that destroys the vascular endothelium. In endovenous laser treatment of varicose veins, a Seldinger technique is used to advance a long catheter along the entire length of the truncal varicosity to be ablated (usually the GSV). A bare laser fiber is passed through the catheter until the end protrudes from the tip of the catheter by approximately 2 cm, and the laser fiber tip is positioned at the SFJ just distal to the subterminal valve. The position is confirmed by means of US and the use of the laser guide light.

Under ultrasound guidance, tumescent solution with a local anesthetic is injected around the entire length of the vessel, separating it from its fascial sheath. This serves to insulate the heat from damaging adjacent structures, including nerves and skin, as well as pain control.

Firm pressure is applied to collapse the vein around the laser fiber, and the laser is fired, generating heat that leads to intraluminal steam bubbles and irreversible endothelial damage and thrombosis. The fiber and catheter are withdrawn approximately 2 mm, and the laser is fired again. This process is repeated along the entire course of the vessel.[27, 22]

Radiofrequency (RF) ablation

In radiofrequency ablation (RFA) of varicose veins, radiogfrequency (RF) thermal energy is delivered directly to the vessel wall, causing protein denaturation, collagenous contraction, and immediate closure of the vessel. Unlike the endovenous laser fiber, the RF catheter actually comes into contact with the lumen walls.

An introducer sheath is inserted into the proposed vein of treatment (again, usually the GSV). A special RF catheter is passed through the sheath and along the vein until the active tip is at the SFJ just distal to the subterminal valve. As with the endovenous laser, tumescent local anesthetic is injected.

Metal fingers at the tip of the RF catheter are deployed until they make contact with the vessel endothelium. RF energy is delivered both in and around the vessel to be treated. Thermal sensors record the temperature within the vessel and deliver just enough energy to ensure endothelial ablation. The RF catheter is withdrawn a short distance, and the process is repeated all along the length of the vein to be treated.

Subramonia and Lees found that in comparison with conventional high ligation and stripping, RFA of GSV varicosities took longer to perform, but patients returned to their normal activities significantly earlier and had significantly less postoperative pain.[28]

Minimally invasive techniques

Cutaneous electrodesiccation

This is an old technique involving electrical cautery for destruction of small vessels. Because of the disfiguring cutaneous injury, it is rarely used today.

Sclerotherapy

Chemical sclerosis of varicose veins has waxed and waned in popularity since the late 1800s. Modern sclerosants with an acceptable risk profile became widely available in the 1930s, and since that time, their use has expanded. Initially, sclerotherapy was used as a surgical adjunct after saphenectomy to treat residual varicosities, reticular veins, or telangiectasias. Currently, it is being used to treat the GSV and main tributaries.

Under US guidance, a sclerosing substance is injected into abnormal vessels to produce endothelial destruction that is followed by formation of a fibrotic cord and eventual reabsorption of all vascular tissue layers (see the image below).

Ultrasound image of the GSV after foam sclerothera Ultrasound image of the GSV after foam sclerotherapy treatment. Note the hyperechogenicity within the vein is from the foam.

Local treatment of the superficial manifestations of venous insufficiency will always fail if the underlying high points of reflux have not been found and treated. Even when the patient appears to have only primary telangiectasias and the initial treatment seems to be successful, recurrences will be seen very quickly if unrecognized reflux exists in larger subsurface vessels.

Caution must be exercised in the use of sclerosing agents. Inadvertent injection into an arteriovenous malformation (AVM) or directly into an unrecognized artery can cause extensive tissue loss or loss of the entire limb. Inadvertent injection of concentrated sclerosants into the deep system can cause DVT, pulmonary embolism (PE), and death.

The most commonly used sclerosants today are polidocanol and sodium tetradecyl sulfate. Both are known as detergent sclerosants because they are amphiphilic substances, inactive in dilute solution but biologically active when they form micelles. These agents are preferred because they have a low incidence of allergic reactions, produce a low incidence of staining and other adverse cutaneous effects, and are relatively forgiving if extravasated. Polidocanol, the most forgiving sclerosing agent, was originally developed as a local anesthetic agent.

Other agents that have fallen out of favor include sodium morrhuate, associated with a relatively high incidence of anaphylaxis. Ethanolamine oleate, a weak detergent, is excessively soluble, decreasing its ability to denature cell surface proteins. Hypertonic saline in a 20% or 23.4% solution can be used as a sclerosing agent, but, because of dilutional effects with injection, it is difficult to achieve adequate sclerosis of large vessels without exceeding a tolerable salt load. If extravasated, it almost invariably causes significant necrosis.

The addition of foam with the sclerosing agents has allowed reduction of the amount of sclerosing agent injected, as well as improved efficacy.[29] Foam pushes blood out of the vein, decreasing dilution and increasing contact of the sclerosant with the endothelium. Homemade foam is usually air-agitated in saline. Because of the theoretical risks of air embolism, commercially available foam consists mostly of carbon dioxide. Varisolve (now known as Varithena in the United States) is one such product, using carbon dioxide foam and polidocanol sclerosant (see the image below).[15, 22]

Varisolve canister and appearance of foam with pol Varisolve canister and appearance of foam with polidocanol.

In the US, sodium tetradecyl sulfate, sodium morrhuate, and ethanolamine oleate were all developed before the establishment of the US Food and Drug Administration (FDA). These agents have never been submitted to the FDA for approval, but they are available in the United States as grandfathered agents. In November 2013, Varithena (Biocompatibles, Oxford, CT) was approved by the FDA for clinical use in the United States.[30]

Postoperative care

After treatment of large varicose veins by any method, a 30- to 40-mm Hg gradient compression stocking is applied, and patients are instructed to maintain or increase their normal activity levels. Most practitioners also recommend the use of gradient compression stockings even after treatment of spider veins and smaller tributary veins.

O'Hare et al found that compression bandaging for 24 hours, followed by use of thromboembolus deterrent stockings for the remainder of 14 days, gave results comparable to compression bandaging for 5 days. In a randomized trial in patients undergoing foam sclerotherapy for primary uncomplicated varicose veins, no significant difference was noted in vein occlusion, phlebitis, skin discoloration, or pain at 2 and 6 weeks with the two techniques.[31]

Ace wraps and other long-stretch bandages should not be used. These elastic bandages fail to maintain adequate compression for more than a few hours. They often slip or are misapplied by patients, with a resulting tourniquet effect that causes distal swelling and increases the risk of DVT.

Activity is particularly important after treatment by any technique because all modalities of treatment for varicose disease have the potential to increase the risk of DVT. Activity is a strong protective factor against venous stasis. Activity is so important that most venous specialists will not treat a patient who is unable to remain active following treatment.

Previous
Next

Complications

A correct diagnosis of superficial venous insufficiency is essential. Veins should be treated only if they are incompetent and if a normal collateral pathway exits. Removal of a saphenous vein with a competent termination will not aid in the management of nontruncal tributary varices.

In the setting of deep system obstruction, varicosities are hemodynamically helpful because they provide a bypass pathway for venous return. Hemodynamically helpful varices must not be removed or sclerosed. Ablation of these varicosities will cause rapid onset of pain and swelling of the extremity, eventually followed by the development of new varicose bypass pathways.

The most annoying minor complications of any venous surgery are dysesthesias from injury to the sural nerve or the saphenous nerve. Subcutaneous hematoma is a common complication, regardless of treatment technique used. It is easily managed with warm compress, nonsteroidal anti-inflammatory drugs (NSAIDs), or aspiration if necessary.

At the SFJ, accidental treatment of the femoral vein by inappropriate RF or laser catheter placement, spread of sclerosant (not visualizing progression with US), and inappropriate surgical ligation can all lead to endothelial damage at the deep vein, causing DVT formation with the potential for PE and even death.[27]

Other complications, such as postoperative infection and arterial injury, are less common and may be kept to a minimum through strict attention to good technique.

Endovenous treatment techniques (with RF and laser therapy) have the potential of excessive tissue heating, which can lead to skin burns. This problem can be avoided if sufficient volumes of tumescent anesthetic are injected to elevate the skin away from the vein.[27]

Previous
 
Contributor Information and Disclosures
Author

Wesley K Lew, MD Fellow, Department of Vascular Surgery, University of California, Los Angeles

Disclosure: Nothing to disclose.

Coauthor(s)

Fred A Weaver, MD, MMM Professor of Surgery, Chief, Division of Vascular Surgery and Endovascular Therapy, Co-Director USC CardioVascular Thoracic Institute; Keck School of Medicine, University of Southern California

Fred A Weaver, MD, MMM is a member of the following medical societies: Alpha Omega Alpha, American Association for the Surgery of Trauma, American College of Surgeons, American Heart Association, American Surgical Association, Association for Academic Surgery, Phi Beta Kappa, Society for Vascular Surgery, Society of University Surgeons, Western Surgical Association, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery

Disclosure: Received consulting fee from CVRx for review panel membership.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

Chief Editor

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

Acknowledgements

Craig F Feied, MD, FACEP, FAAEM, FACPh Professor of Emergency Medicine, Georgetown University School of Medicine; General Manager, Microsoft Enterprise Health Solutions Group

Craig F Feied, MD, FACEP, FAAEM, FACPh is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Phlebology, American College of Physicians, American Medical Association, American Medical Informatics Association, American Venous Forum, Medical Society of the District of Columbia, Society for Academic Emergency Medicine, and Undersea and Hyperbaric Medical Society

Disclosure: Nothing to disclose.

References
  1. Royle J, Somjen GM. Varicose veins: Hippocrates to Jerry Moore. ANZ J Surg. 2007 Dec. 77(12):1120-7. [Medline].

  2. Shami SK, Sarin S, Cheatle TR, Scurr JH, Smith PD. Venous ulcers and the superficial venous system. J Vasc Surg. 1993 Mar. 17(3):487-90. [Medline].

  3. Recek C. Conception of the venous hemodynamics in the lower extremity. Angiology. 2006 Oct-Nov. 57(5):556-63. [Medline].

  4. Weiss RA, Feied CF, Weiss MA. Vein Diagnosis & Treatment: A Comprehensive Approach, 1st ed. New York, NY: McGraw-Hill; 2001.

  5. Pappas PJ, Lal BKL, Cerveira JJ, et al. The Management of Venous Disorders. R. B. Rutherford, ed. Vascular Surgery. Philadelphia, Pennsylvania: Elsevier; 2005. 2220-2302.

  6. Sales CM, Bilof ML, Petrillo KA, Luka NL. Correction of lower extremity deep venous incompetence by ablation of superficial venous reflux. Ann Vasc Surg. 1996 Mar. 10(2):186-9. [Medline].

  7. Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation. 1973 Oct. 48(4):839-46. [Medline].

  8. Callam MJ. Epidemiology of varicose veins. Br J Surg. 1994 Feb. 81(2):167-73. [Medline].

  9. Carpentier PH, Maricq HR, Biro C, Ponçot-Makinen CO, Franco A. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France. J Vasc Surg. 2004 Oct. 40(4):650-9. [Medline].

  10. Lurie F, Creton D, Eklof B, et al. Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population (EVOLVeS Study). J Vasc Surg. 2003 Aug. 38(2):207-14. [Medline].

  11. Lurie F, Creton D, Eklof B, Kabnick LS, Kistner RL, Pichot O. Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up. Eur J Vasc Endovasc Surg. 2005 Jan. 29(1):67-73. [Medline].

  12. Rasmussen LH, Bjoern L, Lawaetz M, Blemings A, Lawaetz B, Eklof B. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg. 2007 Aug. 46(2):308-15. [Medline].

  13. Carradice D, Mekako AI, Mazari FA, Samuel N, Hatfield J, Chetter IC. Clinical and technical outcomes from a randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg. 2011 Aug. 98(8):1117-23. [Medline].

  14. Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg. 2011 Aug. 98(8):1079-87. [Medline].

  15. Wright D, Gobin JP, Bradbury AW, et al. Varisolve® polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebectomy. 2006. 21:180-90.

  16. Obi AT, Reames BN, Rook TJ, Mouch SO, Zarinsefat A, Stabler C, et al. Outcomes associated with ablation compared to combined ablation and transilluminated powered phlebectomy in the treatment of venous varicosities. Phlebology. 2015 Sep 15. [Medline].

  17. Rass K, Frings N, Glowacki P, Gräber S, Tilgen W, Vogt T. Same Site Recurrence is More Frequent After Endovenous Laser Ablation Compared with High Ligation and Stripping of the Great Saphenous Vein: 5 year Results of a Randomized Clinical Trial (RELACS Study). Eur J Vasc Endovasc Surg. 2015 Aug 26. [Medline].

  18. van der Velden SK, Biemans AA, De Maeseneer MG, Kockaert MA, Cuypers PW, Hollestein LM, et al. Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins. Br J Surg. 2015 Sep. 102 (10):1184-94. [Medline].

  19. Hafner J, Ramelet AA, Schmeller W, et al. Management of Leg Ulcers. New York, New York: Karger Publishers; 1999.

  20. Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004 Dec. 40(6):1248-52. [Medline].

  21. Naoum JJ, Hunter GC. Pathogenesis of varicose veins and implications for clinical management. Vascular. 2007 Sep-Oct. 15(5):242-9. [Medline].

  22. Biemans AA, Kockaert M, Akkersdijk GP, van den Bos RR, de Maeseneer MG, Cuypers P, et al. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. J Vasc Surg. 2013 Sep. 58(3):727-34.e1. [Medline].

  23. Kalra M, Gloviczki P. Surgical treatment of venous ulcers: role of subfascial endoscopic perforator vein ligation. Surg Clin North Am. 2003 Jun. 83(3):671-705. [Medline].

  24. Caggiati A, Allegra C. Historical Introduction. The Vein Book. New York, New York: Elsevier; 2006. 1-14.

  25. Dwerryhouse S, Davies B, Harradine K, Earnshaw JJ. Stripping the long saphenous vein reduces the rate of reoperation for recurrent varicose veins: five-year results of a randomized trial. J Vasc Surg. 1999 Apr. 29(4):589-92. [Medline].

  26. Recek C. The hemodynamic paradox as a phenomenon triggering recurrent reflux in varicose vein disease. Int J Angiol. 2012 Sep. 21(3):181-6. [Medline]. [Full Text].

  27. Johnson CM, McLafferty RB. Endovenous laser ablation of varicose veins: review of current technologies and clinical outcome. Vascular. 2007 Sep-Oct. 15(5):250-4. [Medline].

  28. Subramonia S, Lees T. Randomized clinical trial of radiofrequency ablation or conventional high ligation and stripping for great saphenous varicose veins. Br J Surg. 2010 Mar. 97(3):328-36. [Medline].

  29. Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg. 2008 Feb. 35(2):238-45. [Medline].

  30. Varithena [prescribing information]. US Food and Drug Administration. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205098s000lbl.pdf. November 2013; Accessed: October 28, 2015.

  31. O'Hare JL, Stephens J, Parkin D, Earnshaw JJ. Randomized clinical trial of different bandage regimens after foam sclerotherapy for varicose veins. Br J Surg. 2010 May. 97(5):650-6. [Medline]. [Full Text].

 
Previous
Next
 
Pathway leading to varicose veins and other clinical manifestations of venous hypertension.
Telangiectasias.
Reticular veins.
Varicose veins.
Lipodermatosclerosis.
Venous stasis ulcer.
Schematic diagram of the deep and superficial venous systems of the lower extremity: (1) Normal venous drainage; arrows depict the flow of venous blood. (2) Venous hypertension bold arrows are pathways of venous reflux.
Named perforators along the greater saphenous distribution.
Major tributaries of the greater saphenous system.
Saphenofemoral junction.
Perforation-invagination (PIN) stripping schematic.
Ultrasound image of the GSV after foam sclerotherapy treatment. Note the hyperechogenicity within the vein is from the foam.
Varisolve canister and appearance of foam with polidocanol.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.